Skip to Content

Sartorius AG Vorz-Inhaber-Akt ohne Stimmrecht

SRT3: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€726.00KdmwjHczfcmbbft

Sartorius AG Experiencing Tough 2023 Reset, but Long-Term Story Intact

Business Strategy and Outlook

Sartorius AG is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. It offers products and services for life science labs and bioprocessing. For bioprocessing, Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of SRT3 so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center